Results 11 to 20 of about 23,766 (215)

New use of BCG for recombinant vaccines [PDF]

Nature, 1991
BCG, a live attenuated tubercle bacillus, is the most widely used vaccine in the world and is also a useful vaccine vehicle for delivering protective antigens of multiple pathogens. Extrachromosomal and integrative expression vectors carrying the regulatory sequences for major BCG heat-shock proteins have been developed to allow expression of foreign ...
C. K. Stover, V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, S. B. Snapper, R. G. Barletta, W. R. Jacobs, B. R. Bloom   +13 more
openaire   +4 more sources

Recombinant Mycobacterium bovis BCG

Vaccine, 2009
The Bacillus Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens
Reginaldo G, Bastos, Sibele, Borsuk, Fabiana K, Seixas, Odir A, Dellagostin   +3 more
openaire   +4 more sources

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis [PDF]

Nature Medicine, 2003
The live tuberculosis vaccines Mycobacterium bovis BCG (bacille Calmette-Guérin) and Mycobacterium microti both lack the potent, secreted T-cell antigens ESAT-6 (6-kDa early secretory antigenic target) and CFP-10 (10-kDa culture filtrate protein). This is a result of independent deletions in the region of deletion-1 (RD1) locus, which is intact in ...
Alexander S, Pym, Priscille, Brodin, Laleh, Majlessi, Roland, Brosch, Caroline, Demangel, Ann, Williams, Karen E, Griffiths, Gilles, Marchal, Claude, Leclerc, Stewart T, Cole   +9 more
openaire   +4 more sources

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection

Cell Reports, 2017
Recent insights into the mechanisms by which Mycobacterium tuberculosis, the etiologic agent of human tuberculosis, is recognized by cytosolic nucleotide sensors have opened new avenues for rational vaccine design.
Matthias I. Gröschel, Fadel Sayes, Sung Jae Shin, Wafa Frigui, Alexandre Pawlik, Mickael Orgeur, Robin Canetti, Nadine Honoré, Roxane Simeone, Tjip S. van der Werf, Wilbert Bitter, Sang-Nae Cho, Laleh Majlessi, Roland Brosch   +13 more
doaj   +3 more sources

Thirty years of recombinant BCG: new trends for a centenary vaccine

Expert Review of Vaccines, 2021
Introduction: Global perception of the potential for Bacille Calmette-Guérin (BCG), and consequently recombinant BCG (rBCG), in a variety of prophylactic and therapeutic applications has been increasing. A century of information on BCG, and three decades of experience with rBCG, has generated solid knowledge in this field. Area covered: Here, we review
Lazaro M Marques-Neto, Zuzanna Piwowarska, Alex I. Kanno, Luana Moraes, Monalisa M Trentini, Dunia Rodriguez, Jose L. S. C. Silva, Luciana C. C. Leite   +7 more
openaire   +4 more sources

Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery [PDF]

, 2013
Protein-based vaccine development faces the difficult challenge of finding robust yet non-toxic adjuvants suitable for humans. Here, using a molecular engineering approach, we have developed a molecular platform for generating self-adjuvanting immunogens
A Demissie, A Raja, A Regnault, A Williams, AF Cunningham, AN Antoniou, AR Berengian, AS Mustafa, B Heyman, BC Schalke, CK Kennaway, Craig van Dolleweerd, CT Cady, D Chargelegue, D Matheoud, DH Schuurhuis, E Celis, E Celis, EJ Wiersma, Elena Stylianou, EM Leyten, F Manca, F Pinheiro da Silva, F Villinger, F Winau, G Falero-Diaz, G Terres, GG Klaus, Gil Reynolds Diogo, H Boesen, Ilaria Pepponi, J Laissue, JM den Haan, Julian K.-C. Ma, K Osato, KB Reid, M Jacobsen, Matthew J. Paul, MF Bachmann, N Caccamo, N Polyanskaya, P Andersen, Pascal M. W. Drake, PD Simitsek, Pere-Joan Cardona, PM Guyre, PM Hogarth, PS Jackett, Q Li, R Jemmerson, R Pal, R Reljic, R Reljic, Rajko Reljic, RG Taylor, RJ Eisenberg, RJ Wilkinson, S Marusic-Galesic, SA Moreno-Mendieta, SA Plotkin, U Abdel-Motal, V Roupie, W Phoolcharoen, WE Houston, WR Heath, Y Yuan, Y Yuan, YM Wen, Z Chang   +68 more
core   +17 more sources

Engineering a dual vaccine against COVID-19 and tuberculosis

Frontiers in Cellular and Infection Microbiology, 2023
The COVID-19 pandemic, caused by SARS-CoV-2 virus, has been one of the top public health threats across the world over the past three years. Mycobacterium bovis BCG is currently the only licensed vaccine for tuberculosis, one of the deadliest infectious ...
Carlyn Monèt Guthrie, Carlyn Monèt Guthrie, Xuejuan Tan, Xuejuan Tan, Amber Cherry Meeker, Amber Cherry Meeker, Ashton Elisabeth Self, Ashton Elisabeth Self, Lin Liu, Lin Liu, Yong Cheng, Yong Cheng   +11 more
doaj   +1 more source

Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. [PDF]

PLoS Neglected Tropical Diseases, 2016
Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells ...
Bryan E Hart, Sunhee Lee
doaj   +1 more source

Protease-Based Subunit Vaccine in Mice Boosts BCG Protection against Mycobacterium tuberculosis

Vaccines, 2022
The significant number of people with latent and active tuberculosis infection requires further efforts to develop new vaccines or improve the Bacillus Calmette-Guérin (BCG), which is the only approved vaccine against this disease.
Ana Paula Junqueira-Kipnis, Carine de Castro Souza, Ana Carolina de Oliveira Carvalho, Fabio Muniz de Oliveira, Vinnycius Pereira Almeida, Alisson Rodrigues de Paula, Mara Rubia Celes, André Kipnis   +7 more
doaj   +1 more source

The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen. [PDF]

PLoS ONE, 2014
Numerous features make Mycobacterium bovis BCG an attractive vaccine vector for HIV. It has a good safety profile, it elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable.
Rosamund Chapman, William R Bourn, Enid Shephard, Helen Stutz, Nicola Douglass, Thandi Mgwebi, Ann Meyers, Nyasha Chin'ombe, Anna-Lise Williamson   +8 more
doaj   +1 more source